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Hemolytic Uremic Syndrome
Along with a report of the first outbreak of
hemolytic uremic syndrome (HUS) caused by
Shiga-like toxin (SLT) producing E. coli in Austra-
lia (1), this issue of Emerging Infectious Diseases
presents three papers detailing the investigations
of pediatric HUS cases linked to Shiga toxin (ST)
and SLT producing bacteria. Goldwater and Bet-
telheim present a case of pediatric HUS associ-
ated with SLT producing Escherichia coli (SLTEC)
O48:H21 in South Australia; this strain has not
previously been recognized as an SLTEC. Saeed
et al. report on the increasingly common identifi-
cation of HUS in Saudi Arabia, its association with
multiple-antibiotic-resistant Shigella dysenteriae
type 1, and the inherent dangers of treating such
patients with ampicillin and nalidixic acid. Al-
Qawari et al. report on the results of active sur-
veillance for dysentery and HUS in Saudi Arabia
and discuss a possibly elevated risk for HUS in
patients with bloody diarrhea who are hospital-
ized and treated with nalidixic acid during an
outbreak of S. dysenteriae type 1.
The three papers raise a number of important
issues regarding HUS. First, it is clear that a large
number of SLT producing bacteria have the poten-
tial to cause HUS, particularly among children.
Current research has focused on E. coli O157:H7,
which since the early 1980s has emerged as a
major foodborne cause of bloody diarrhea, hemor-
rhagic colitis, and HUS since the early 1980s (5-7).
However, the large outbreak of pediatric HUS in
South Australia in 1995 caused by foodborne E.
coli O111:HNM has demonstrated that minor
pathogens can emerge as major causes of HUS (1).
Goldwater and Bettelheim (5) and other re-
searchers have identified a number of E. coli sero-
types isolated from patients with HUS (6,7).
A-Qawari et al. and Saeed et al. offer a timely
reminder that S. dysenteriae type 1, a pathogen
with a human-only reservoir, is an equally serious
contender in HUS etiology and pathogenesis when
conditions facilitate the person-to-person trans-
mission of pathogens.
The second key issue raised by the latter two
papers concerns treatment of bloody diarrhea.
Both discuss the potential for antibiotic (am-
picillin and nalidixic acid)-mediated HUS and
conclude that this issue should be carefully evalu-
ated before antibiotics are used to manage bloody
diarrhea. Saeed et al. note that the wide variety
of antibiotics used to treat bloody diarrhea in
Saudi Arabia could be explained by the various
prescription practices of doctors recruited from
different parts of the world. Antibiotic resistance
is a worrying component of the mechanisms of
emerging infectious diseases. Inappropriate anti-
biotic use is a key factor in the development of
resistance, and major efforts must be directed
towards educating physicians on effective pre-
scribing practices.
Central to all three papers is the need for sur-
veillance of organisms that cause bloody diarrhea,
hemorrhagic colitis, and HUS, as well as for
knowledge of the local epidemiology of SLTECs,
their potential sources, and the optimal way to
investigate and manage outbreaks. Goldwater
and Bettelheim discuss the characteristic disap-
pearance of E. coli from patients’ stools after the
development of HUS and, therefore, the impor-
tance of early detection in cases of bloody diar-
rhea. Laboratory testing of bloody diarrheal
specimens is clearly critical to understanding the
epidemiology of toxin-producing organisms that
relate to the development of HUS (8). However,
testing can be difficult, time-consuming and
costly. Not all laboratories routinely test for
SLTECs or have the capacity to do so. In Australia,
for example, using polymerase chain reaction
(PCR) technology to detect SLT genes is expen-
sive: a negative test result costs approximately
$A15, but if the results are positive, the cost rises
to around $A250 when the SLTEC is isolated and
typed.
Human surveillance is essential to the early
detection of outbreaks and to the critical assess-
ment of the impact on public health of new ap-
proaches to food safety (2,8). We conservatively
estimate that the South Australian HUS outbreak
has cost around $A20 million in direct and indirect
costs, with major impacts being felt by industry.
This must surely be considered when contemplat-
ing the costs of surveillance. One approach may
be to use PCR techniques on all samples of bloody
diarrhea in children under the age of 16 because
if surveillance is to be effective, it must be specific
(9). Intermittent surveys, or the use of sentinel
laboratories for all cases of diarrhea (8) could be
undertaken and mandatory notification of HUS
instituted.
Compulsory notification of Shigella infection is
a requirement in Australia, and including
SLTECs on the list of notifiable diseases is being
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HUS was established in 1994, although notifica-
tion is not mandatory. Without formal notification
requirements, good reporting of HUS has been
associated with either clustering of cases or the
fact that few hospitals in a region have the capac-
ity to manage these cases (10).
Although more attention has been focused on
E. coli O157:H7, S. dysenteriae is likely the most
common cause of HUS in children worldwide and
more attention needs to be given to this pathogen
in terms of surveillance and control. A strong and
healthy public health infrastructure is required to
address the infectious disease issues raised by
HUS (11).
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